Apply on Employer Site

Fred Hutch · 1 day ago

Leukemia Program Head

Seattle, WA

Full-time

Onsite

Director/Executive

$411K/yr - $463K/yr

Fred Hutchinson Cancer Center is a leading cancer research institution based in Seattle, and they are seeking a highly motivated and accomplished individual to lead their Leukemia Program. The Program Head will oversee research and clinical programs in acute myeloid leukemia and myeloid malignancies, guiding strategic initiatives and fostering collaborations within the institution.

Hospital & Health Care

No H1B

Responsibilities

Oversee the research and clinical programs in acute myeloid leukemia (AML) and other myeloid malignancies

Develop and implement a comprehensive vision and strategy for AML and myeloid malignancies throughout the entire disease spectrum, integrating basic, translational and clinical research with clinical care

Lead and/or support groundbreaking research initiatives, including preclinical studies, clinical trials, and translational research

Foster collaborations with bench researchers, translational researchers and clinical investigators at UW and Fred Hutch

Organize, direct and expand the research efforts for an established team of clinical researchers involved in conducting trials

Assist with faculty recruitment as well as oversight and mentorship of faculty

Promote professional development for team members

Represent the Program at national and international conferences, workshops, and symposia

Build and maintain strong relationships with external stakeholders, including industry partners, regulatory agencies, and funding organizations

Qualification

MD/DO degreeBoard certification in hematologyBoard certification in medical oncologyResearch in AMLClinical trial experienceLeadership experienceMentorshipCollaboration

Required

MD/DO degree (or foreign equivalent)

Board certification in hematology and/or medical oncology (or foreign equivalent)

Eligibility for medical licensure in the state of Washington

Record of and primary interest in AML and/or myeloid malignancies research, as demonstrated by peer-reviewed publications, grants and/or clinical trial experience